Cargando…

Neutralizing-antibody response to SARS-CoV-2 for 12 months after the COVID-19 workplace outbreaks in Japan

This study aimed to elucidate the 12-month durability of neutralizing antibodies (NAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients infected during the 2020 workplace outbreaks of coronavirus disease 2019 (COVID-19) in Japan. We followed 33 Japanese patients infe...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishizaki, Azumi, Bi, Xiuqiong, Nguyen, Quynh Thi, Maeno, Tomomi, Hara, Akinori, Nakamura, Hiroyuki, Kuramoto, Sanae, Nishi, Koichi, Ooe, Hiroyasu, Ichimura, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426944/
https://www.ncbi.nlm.nih.gov/pubmed/36040882
http://dx.doi.org/10.1371/journal.pone.0273712
_version_ 1784778792669020160
author Ishizaki, Azumi
Bi, Xiuqiong
Nguyen, Quynh Thi
Maeno, Tomomi
Hara, Akinori
Nakamura, Hiroyuki
Kuramoto, Sanae
Nishi, Koichi
Ooe, Hiroyasu
Ichimura, Hiroshi
author_facet Ishizaki, Azumi
Bi, Xiuqiong
Nguyen, Quynh Thi
Maeno, Tomomi
Hara, Akinori
Nakamura, Hiroyuki
Kuramoto, Sanae
Nishi, Koichi
Ooe, Hiroyasu
Ichimura, Hiroshi
author_sort Ishizaki, Azumi
collection PubMed
description This study aimed to elucidate the 12-month durability of neutralizing antibodies (NAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients infected during the 2020 workplace outbreaks of coronavirus disease 2019 (COVID-19) in Japan. We followed 33 Japanese patients infected with SARS-CoV-2 in April 2020 for 12 months (12M). Patients were tested for NAbs and for antibodies against the SARS-CoV-2 nucleocapsid (anti-NC-Ab) and antibodies against the spike receptor-binding domain (anti-RBD-Ab). Tests were performed at 2M, 6M, and 12M after the primary infection (api) with commercially available test kits. In 90.9% (30/33) of patients, NAbs persisted for 12M api, though the median titers significantly declined from 78.7% (interquartile range [IQR]: 73.0–85.0%) at 2M, to 59.8% (IQR: 51.2–77.9) at 6M (P = 0.008), and to 56.2% (IQR: 39.6–74.4) at 12M (P<0.001). An exponential decay model showed that the NAb level reached undetectable concentrations at 35.5 months api (95% confidence interval: 26.5–48.0 months). Additionally, NAb titers were significantly related to anti-RBD-Ab titers (rho = 0.736, P<0.001), but not to anti-NC-Ab titers. In most patients convalescing from COVID-19, NAbs persisted for 12M api. This result suggested that patients need a booster vaccination within one year api, even though NAbs could be detected for over two years api. Anti-RBD-Ab titers could be used as a surrogate marker for predicting residual NAb levels.
format Online
Article
Text
id pubmed-9426944
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-94269442022-08-31 Neutralizing-antibody response to SARS-CoV-2 for 12 months after the COVID-19 workplace outbreaks in Japan Ishizaki, Azumi Bi, Xiuqiong Nguyen, Quynh Thi Maeno, Tomomi Hara, Akinori Nakamura, Hiroyuki Kuramoto, Sanae Nishi, Koichi Ooe, Hiroyasu Ichimura, Hiroshi PLoS One Research Article This study aimed to elucidate the 12-month durability of neutralizing antibodies (NAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients infected during the 2020 workplace outbreaks of coronavirus disease 2019 (COVID-19) in Japan. We followed 33 Japanese patients infected with SARS-CoV-2 in April 2020 for 12 months (12M). Patients were tested for NAbs and for antibodies against the SARS-CoV-2 nucleocapsid (anti-NC-Ab) and antibodies against the spike receptor-binding domain (anti-RBD-Ab). Tests were performed at 2M, 6M, and 12M after the primary infection (api) with commercially available test kits. In 90.9% (30/33) of patients, NAbs persisted for 12M api, though the median titers significantly declined from 78.7% (interquartile range [IQR]: 73.0–85.0%) at 2M, to 59.8% (IQR: 51.2–77.9) at 6M (P = 0.008), and to 56.2% (IQR: 39.6–74.4) at 12M (P<0.001). An exponential decay model showed that the NAb level reached undetectable concentrations at 35.5 months api (95% confidence interval: 26.5–48.0 months). Additionally, NAb titers were significantly related to anti-RBD-Ab titers (rho = 0.736, P<0.001), but not to anti-NC-Ab titers. In most patients convalescing from COVID-19, NAbs persisted for 12M api. This result suggested that patients need a booster vaccination within one year api, even though NAbs could be detected for over two years api. Anti-RBD-Ab titers could be used as a surrogate marker for predicting residual NAb levels. Public Library of Science 2022-08-30 /pmc/articles/PMC9426944/ /pubmed/36040882 http://dx.doi.org/10.1371/journal.pone.0273712 Text en © 2022 Ishizaki et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Ishizaki, Azumi
Bi, Xiuqiong
Nguyen, Quynh Thi
Maeno, Tomomi
Hara, Akinori
Nakamura, Hiroyuki
Kuramoto, Sanae
Nishi, Koichi
Ooe, Hiroyasu
Ichimura, Hiroshi
Neutralizing-antibody response to SARS-CoV-2 for 12 months after the COVID-19 workplace outbreaks in Japan
title Neutralizing-antibody response to SARS-CoV-2 for 12 months after the COVID-19 workplace outbreaks in Japan
title_full Neutralizing-antibody response to SARS-CoV-2 for 12 months after the COVID-19 workplace outbreaks in Japan
title_fullStr Neutralizing-antibody response to SARS-CoV-2 for 12 months after the COVID-19 workplace outbreaks in Japan
title_full_unstemmed Neutralizing-antibody response to SARS-CoV-2 for 12 months after the COVID-19 workplace outbreaks in Japan
title_short Neutralizing-antibody response to SARS-CoV-2 for 12 months after the COVID-19 workplace outbreaks in Japan
title_sort neutralizing-antibody response to sars-cov-2 for 12 months after the covid-19 workplace outbreaks in japan
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426944/
https://www.ncbi.nlm.nih.gov/pubmed/36040882
http://dx.doi.org/10.1371/journal.pone.0273712
work_keys_str_mv AT ishizakiazumi neutralizingantibodyresponsetosarscov2for12monthsafterthecovid19workplaceoutbreaksinjapan
AT bixiuqiong neutralizingantibodyresponsetosarscov2for12monthsafterthecovid19workplaceoutbreaksinjapan
AT nguyenquynhthi neutralizingantibodyresponsetosarscov2for12monthsafterthecovid19workplaceoutbreaksinjapan
AT maenotomomi neutralizingantibodyresponsetosarscov2for12monthsafterthecovid19workplaceoutbreaksinjapan
AT haraakinori neutralizingantibodyresponsetosarscov2for12monthsafterthecovid19workplaceoutbreaksinjapan
AT nakamurahiroyuki neutralizingantibodyresponsetosarscov2for12monthsafterthecovid19workplaceoutbreaksinjapan
AT kuramotosanae neutralizingantibodyresponsetosarscov2for12monthsafterthecovid19workplaceoutbreaksinjapan
AT nishikoichi neutralizingantibodyresponsetosarscov2for12monthsafterthecovid19workplaceoutbreaksinjapan
AT ooehiroyasu neutralizingantibodyresponsetosarscov2for12monthsafterthecovid19workplaceoutbreaksinjapan
AT ichimurahiroshi neutralizingantibodyresponsetosarscov2for12monthsafterthecovid19workplaceoutbreaksinjapan